IACH 2021 | Advances in BPDCN
Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives an update on the the latest advances in the field of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic bone marrow malignancy. Dr Pemmaraju discusses the use of the CD123-targeting agent tagraxofusp, as well as novel agents such as IMGN632 which has received breakthrough therapy designation in relapsed/refractory BODCN. Dr Pemmaraju also comments on the use of the BCL-2 inhibitor venetoclax and the discovery that central nervous system involvement is very high in BPDCN, commenting on how this has impacted treatment approaches. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.
